<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
h4
{mso-style-priority:9;
mso-style-link:"Heading 4 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.articleimagecaption
{mso-style-name:articleimagecaption;}
span.Heading4Char
{mso-style-name:"Heading 4 Char";
mso-style-priority:9;
mso-style-link:"Heading 4";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;
font-style:italic;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1680809103;
mso-list-template-ids:-2027389534;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Interesting article.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><div><h1>MRI-Ultrasound Fusion Biopsy Detects High-Grade Prostate Cancer<o:p></o:p></h1><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal><img id="_x0000_i1025" src="http://media.renalandurologynews.com/images/2015/11/06/hcvupsanemiaeventriskshem_864036.jpg?format=jpg&zoom=1&quality=70&anchor=middlecenter&width=320&mode=pad" alt="More high-grade cancers detected with MRF-TB vs. systematic biopsy in men undergoing primary biopsy."><br><span class=articleimagecaption>More high-grade cancers detected with MRF-TB vs. systematic biopsy in men undergoing primary biopsy.</span> <o:p></o:p></p></div><p>(HealthDay News) -- Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy (MRF-TB) improves detection and risk stratification of high-grade disease and limits detection of clinically insignificant prostate cancer, according to a study published in <i>The Journal of Urology</i>.<o:p></o:p></p><p>Neil Mendhiratta, from the New York University Langone Medical Center in New York City, and colleagues reported clinical outcomes for 452 consecutive men presenting for primary prostate biopsy. Participants underwent prebiopsy multiparametric magnetic resonance imaging followed by MRF-TB and systematic biopsy.<o:p></o:p></p><p>The researchers detected<a href="http://www.renalandurologynews.com/prostate-cancer/section/618/"> prostate cancer</a> in 54.2% of 382 men (mean age, 64 years; mean prostate-specific antigen, 6.8 ng/mL) who met inclusion criteria. The cancer detection rate was 49.2% for systematic biopsy and 43.5% for MRF-TB <i>(P = 0.006)</i>. Compared with systematic biopsy, MRF-TB detected more Gleason score 7 or greater cancers (88.6% versus 77.3%; <i>P = 0.037</i>). Overall, 82.9% of the 41 cancers detected by systematic biopsy but not by MRF-TB demonstrated Gleason 6 disease, and 63.4% and 82.9%, respectively, were clinically insignificant by Epstein criteria and a University of California-San Francisco-Cancer of the Prostate Risk Assessment score of 2 or less.<o:p></o:p></p><p>"Prebiopsy magnetic resonance imaging followed by MRF-TB decreases the detection of low-risk cancers while significantly improving the detection and risk stratification of high-grade disease," the authors write.<o:p></o:p></p><h4>Source<o:p></o:p></h4><ol start=1 type=1><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1'><a href="http://www.jurology.com/article/S0022-5347%2815%2904213-5/fulltext" target="_new">Mendhiratta N, Rosenkrantz AB, Meng X, et al. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy. <i>The Journal of Urology</i> 194;1601–1606. doi: 10.1016/j.juro.2015.06.078.</a><o:p></o:p></li></ol><p><o:p> </o:p></p><p><o:p> </o:p></p><p><a href="url:http://www.renalandurologynews.com/prostate-cancer/mri-ultrasound-fusion-biopsy-detects-high-grade-prostate-cancer/article/454471/">url:http://www.renalandurologynews.com/prostate-cancer/mri-ultrasound-fusion-biopsy-detects-high-grade-prostate-cancer/article/454471/</a><o:p></o:p></p></div><p class=MsoNormal>-- <br>You received this message because you are subscribed to the Google Groups "FYI Prostate Info" group.<br>To unsubscribe from this group and stop receiving emails from it, send an email to <a href="mailto:fyi-prostate-info+unsubscribe@googlegroups.com">fyi-prostate-info+unsubscribe@googlegroups.com</a>.<br>To post to this group, send email to <a href="mailto:fyi-prostate-info@googlegroups.com">fyi-prostate-info@googlegroups.com</a>.<br>To view this discussion on the web visit <a href="https://groups.google.com/d/msgid/fyi-prostate-info/d7a239c9-a83d-46b9-adf2-b8058e150ba2%40googlegroups.com?utm_medium=email&utm_source=footer">https://groups.google.com/d/msgid/fyi-prostate-info/d7a239c9-a83d-46b9-adf2-b8058e150ba2%40googlegroups.com</a>.<br>For more options, visit <a href="https://groups.google.com/d/optout">https://groups.google.com/d/optout</a>.<o:p></o:p></p></div></body></html>